Reimbursement

CMMI’s “New Direction” Comments Indicate Enthusiasm of Healthcare Stakeholders

Dave Terry describes how feedback to a CMS announcement last fall has spurred another request.

Dave Terry May 22, 2018

How MA Plans Are Changing VBID Approaches

May 18—Medicare Advantage (MA) plans are evolving their approaches in the expanding Medicare pilot for value-based insurance design (VBID).

Rich Daly May 21, 2018

Methodology Used to Identify Top Procedures Performed at Hospitals and Free-Standing Clinics

Recent research on hospital versus free-standing facility pricing used 2016 Medicare hospital OPPS data as its basis.

HFMA May 18, 2018

A Look at Two Blues’ Distinct Approaches to Changing the Healthcare Model

May 16—Two dominant not-for-profit health plans—both Blue Cross insurers—are moving aggressively in very different directions.

Rich Daly May 17, 2018

Decoding MSPB: Trending Better Faster

Dale Schumacher and Fern Nerhood describe how trends in Medicare spending per beneficiary can affect hospital finances.

Dale N. Schumacher May 16, 2018

340B Targeted in Trump Administration Drug Push

May 15—Hospital advocates and others raised concerns about impacts of the Trump administration’s recently announced initiative to address rapidly rising drug prices in part through policy changes to an existing drug discount program.

Rich Daly May 15, 2018

FY2019 Skilled Nursing Facility Proposed Rule Summary

This document summarizes the FY2019 proposed rule updating the skilled nursing facility (SNF) payment rates.

HFMA May 15, 2018

Former CMS Leaders: ACO Changes Are Coming

May 11—Medicare accountable care organizations (ACOs) are likely to face an imminent overhaul, according to former leaders of the program.

Rich Daly May 14, 2018

Competing with Freestanding Outpatient Centers—Where to Focus on Pricing

Price reductions should be included in pricing strategies to help hospitals better compete with these free-standing centers.

Scott Houk May 11, 2018

May 14-18: Senate Holds 340B Hearing Amid Surge in Activity

May 10—Congress will once again examine the 340B discount drug program next week amid several judicial and regulatory developments related to the program.

Rich Daly May 10, 2018
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-leaderboard' ); } );